Robert-Jan Raterink
Profile
Robert-Jan Raterink held the position of Chief Executive Officer at TIM BV.
He also worked as the Managing Director & Director at DUCARES BV from 2020 to 2021.
Former positions of Robert-Jan Raterink
| Companies | Position | End |
|---|---|---|
TIM BV
 TIM BV Miscellaneous Commercial ServicesCommercial Services TIM BV is a Dutch research company that specializes in performance evaluation of oral drugs. The company is based in Delft, Netherlands. The company leverages their proprietary and bio-predictive in vitro technology to support decision-making during oral drug development, which helps to de-risk the development trajectory. The CEO of the company is Robert-Jan Raterink. | Chief Executive Officer | 28/11/2023 |
DUCARES BV
 DUCARES BV Miscellaneous Commercial ServicesCommercial Services DUCARES BV engages in the provision of research laboratory services. The firm also organizes proficiency tests for international laboratories. It specializes in the development and performance of analyzes for food safety, food quality, animal health, and welfare. The company was founded on January 1, 2008 and is headquartered in Utrecht, the Netherlands. | Chief Executive Officer | 01/09/2021 |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
DUCARES BV
DUCARES BV Miscellaneous Commercial ServicesCommercial Services DUCARES BV engages in the provision of research laboratory services. The firm also organizes proficiency tests for international laboratories. It specializes in the development and performance of analyzes for food safety, food quality, animal health, and welfare. The company was founded on January 1, 2008 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
TIM BV
TIM BV Miscellaneous Commercial ServicesCommercial Services TIM BV is a Dutch research company that specializes in performance evaluation of oral drugs. The company is based in Delft, Netherlands. The company leverages their proprietary and bio-predictive in vitro technology to support decision-making during oral drug development, which helps to de-risk the development trajectory. The CEO of the company is Robert-Jan Raterink. | Commercial Services |
- Stock Market
- Insiders
- Robert-Jan Raterink
